Edition:
United Kingdom

Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

0.40CAD
14 Dec 2018
Change (% chg)

$0.00 (+1.27%)
Prev Close
$0.40
Open
$0.40
Day's High
$0.41
Day's Low
$0.38
Volume
900,300
Avg. Vol
937,010
52-wk High
$1.80
52-wk Low
$0.36

Latest Key Developments (Source: Significant Developments)

Prometic Reports Third Quarter 2018 Financial Results
Thursday, 15 Nov 2018 

Nov 14 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS.Q3 REVENUE C$12.3 MILLION.PROMETIC LIFE SCIENCES- INCURRED A NET LOSS OF $28.9 MILLION FOR Q3 ENDED SEPTEMBER 30, 2018 COMPARED TO A NET LOSS OF $17.8 MILLION FOR Q3 2017.  Full Article

Prometic Announces Extension Of Debt Maturities To 2024
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Prometic Life Sciences Inc ::PROMETIC ANNOUNCES EXTENSION OF DEBT MATURITIES TO 2024.PROMETIC LIFE SCIENCES - SIGNED LOI WITH STRUCTURED ALPHA TO EXTEND MATURITY DATES OF $80 MILLION LINE OF CREDIT AND ORIGINAL ISSUE DISCOUNT NOTES.  Full Article

Prometic Life Sciences Incurred Net Loss Of $34.6 Mln For Quarter
Tuesday, 15 May 2018 

May 15 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS ITS 2018 FIRST QUARTER HIGHLIGHTS AND FINANCIAL RESULTS.PROMETIC LIFE SCIENCES INC - TOTAL REVENUES FOR Q1 ENDED MARCH 31, 2018 WERE $4.3 MILLION COMPARED TO $4.9 MILLION FOR Q1 ENDED MARCH 31, 2017.PROMETIC LIFE SCIENCES INC - CORP INCURRED NET LOSS OF $34.6 MILLION FOR QUARTER VERSUS A NET LOSS OF $29.1 MILLION.  Full Article

Prometic Reports Positive Clinical Data From Its Intravenous Immunoglobulin Pivotal Phase 3 Trial
Monday, 30 Apr 2018 

April 30 (Reuters) - Prometic Life Sciences Inc ::PROMETIC REPORTS POSITIVE CLINICAL DATA FROM ITS INTRAVENOUS IMMUNOGLOBULIN (IVIG) PIVOTAL PHASE 3 TRIAL.PROMETIC LIFE SCIENCES INC - PIVOTAL CLINICAL TRIAL MEETS PRIMARY AND SECONDARY ENDPOINTS.PROMETIC LIFE SCIENCES INC - CLINICAL DATA DEMONSTRATES COMPARABLE EFFICACY TO COMMERCIALLY-APPROVED DRUG.PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES.PROMETIC LIFE SCIENCES INC - PROMETIC IVIG'S SAFETY AND TOLERABILITY PROFILES MAINTAINED WITHOUT ANY SIGNIFICANT DRUG RELATED ISSUES.PROMETIC LIFE SCIENCES INC - OVERALL PROMETIC IGIV 10% APPEARED TO BE WELL TOLERATED AND WAS NOT ASSOCIATED WITH ANY SBIS.  Full Article

Prometic reports positive interim clinical data from IVIG phase 3 trial
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Prometic Life Sciences Inc :Prometic reports positive interim clinical data from ongoing intravenous immunoglobulin (IVIG) pivotal phase 3 trial.Prometic Life Sciences Inc - ‍interim clinical data shows non inferiority to commercially-approved products for primary immunodeficiencies​.Prometic Life Sciences - ‍clinical data confirmed no significant safety issues, efficacy appeared to be comparable to existing commercial IVIG products​.  Full Article

Prometic Q3 revenue C$24 million versus C$3.7 million
Tuesday, 14 Nov 2017 

Nov 13 (Reuters) - Prometic Life Sciences Inc :Prometic reports 2017 third quarter highlights and financial results.Q3 revenue C$24 million versus C$3.7 million.Q3 revenue view c$6.9 million -- Thomson Reuters I/B/E/S.Prometic Life Sciences - ‍incurred a net loss of $17.8 million for quarter ended sept 30, compared to net loss of $28.0 million for quarter ended Sept 30, 2016​.  Full Article

Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Prometic Life Sciences Inc ::Prometic receives clearance from the Swedish Medical Products Agency to initiate plasminogen clinical trial in chronic tympanic membrane perforation.Prometic Life Sciences Inc - ‍up to 33 adult patients are expected to be enrolled in clinical trial​.  Full Article

Prometic enters LOI for $80 mln line of credit from Structured Alpha LP
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Prometic Life Sciences Inc ::Prometic enters into binding letter of intent to secure usd $80 million (CAD $100 million) line of credit from Structured Alpha LP, an affiliate of Thomvest Asset Management Inc.Company to grant Structured Alpha LP an initial 10 million warrants with an exercise price of CAD $1.70 per common share​.Company to also grant Structured Alpha LP additional 44 million warrants at exercise price of CAD $1.70 per common share​.  Full Article

FDA accepts Prometic's Biologics License Application for Plasminogen
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Prometic Life Sciences Inc :Prometic announces FDA acceptance of its Biologics License Application for Plasminogen (Ryplazim™).Prometic Life Sciences Inc - ‍prescription Drug User Fee Act (PDUFA) action date is set for April 14, 2018​.  Full Article

CANADA STOCKS - TSX dips 0.09 percent, but higher for the week

NEW YORK, June 15 * The Toronto Stock Exchange's S&P/TSX fell 14.54 points, or 0.09 percent, to 16,314.42 but climbed 0.69 percent on the week, its second straight weekly gain. * The biggest contributor to the TSX loss was Toronto-Dominion Bank, pulling 7.6 points from the index. Energy was the heaviest sector drag, with 32.3 net points. * Leading the index were Canada Goose Holdings Inc, up 30 percent in the wake of its quarterly results, Paramount Resources Ltd, up 4 percent, and P